Survey on the International Staging System and Chromosome Analysis Test in Multiple Myeloma Therapy

Survey on the International Staging System and Chromosome Analysis Test in Multiple Myeloma Therapy - Survey on the International Staging System and Chromosome Analysis Test in Multiple Myeloma Therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054709

Enrollment

150

Registered

2024-06-19

Start date

2024-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who meet all of the following inclusion criteria will be included: 1_Belong to the department of hematology 2_Work at a hospital (with 80 beds or more) 3_Treated "1 or more patients with multiple myeloma in the last year." 4_Treated "1 or more patients with multiple myeloma in the last year." 5_Agreed to participate in the survey

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To grasp current use of the international staging system in multiple myeloma (MM) and describe the awareness and use of the newly established R2-ISS. 1_Current use of each international staging system 2_Thoughts on international staging system 3_Awareness of R2-ISS 4_Current use of R2-ISS 5_Intension to use R2-ISS and the reasons	—

Secondary

Measure	Time frame
I. To describe the thoughts on and issues with the chromosome analysis test for MM treatment and the current measurement of 1q21gain/amplification. II. To clarify the prospect for the chromosome analysis test as a prognostic factor in the future 1_Current use of chromosome analysis test 2_Thoughts on and issues with the chromosome analysis test 3_Current measurement of 1q21gain/amplification 4_How the 1q21gain/amplification result is used 5_Thoughts on 1q21gain/amplification measurement	—

Measure

Time frame

I. To describe the thoughts on and issues with the chromosome analysis test for MM treatment and the current measurement of 1q21gain/amplification. II. To clarify the prospect for the chromosome analysis test as a prognostic factor in the future 1_Current use of chromosome analysis test 2_Thoughts on and issues with the chromosome analysis test 3_Current measurement of 1q21gain/amplification 4_How the 1q21gain/amplification result is used 5_Thoughts on 1q21gain/amplification measurement

—

Countries

Japan

Contacts

Public ContactTomoyuki Kusaka

Social Survey Research Information Co., Ltd. Healthcare Business Intelligence Service Division

HOR@ssri.com03-6709-9710

Outcome results